Henlius NDA for 120 mg denosumab biosimilar accepted by NMPA
Shanghai Henlius Biotech says China’s NMPA accepted its NDA for HLX14, a 120 mg denosumab biosimilar.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.